Sylvain Barreau

ORCID: 0000-0002-5566-7369
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Immunodeficiency and Autoimmune Disorders
  • Pediatric Pain Management Techniques
  • Cancer, Hypoxia, and Metabolism
  • Attention Deficit Hyperactivity Disorder
  • Renal and related cancers
  • Empathy and Medical Education
  • Historical and Scientific Studies
  • Single-cell and spatial transcriptomics
  • CAR-T cell therapy research
  • Cancer Treatment and Pharmacology
  • Mast cells and histamine
  • Antimicrobial Resistance in Staphylococcus
  • Acute Lymphoblastic Leukemia research
  • Drug-Induced Adverse Reactions
  • Digital Imaging for Blood Diseases
  • Parvovirus B19 Infection Studies
  • Urticaria and Related Conditions
  • Autism Spectrum Disorder Research
  • Antibiotics Pharmacokinetics and Efficacy
  • Orthopedic Infections and Treatments

Assistance Publique – Hôpitaux de Paris
2019-2024

Université Paris-Saclay
2023-2024

Inserm
2019-2024

Université de Versailles Saint-Quentin-en-Yvelines
2024

Bicêtre Hospital
2024

Hôpital Paul-Brousse
2023

Université Paris Cité
2009-2021

Hôpital Cochin
2020-2021

Institut Necker Enfants Malades
2020

Hôpital Necker-Enfants Malades
2020

Background Reports of reduced pain sensitivity in autism have prompted opioid theories and practical care ramifications. Our objective was to examine behavioral physiological responses, plasma β-endorphin levels their relationship a large group individuals with autism. Methodology/Principal Findings The study conducted on 73 children adolescents 115 normal matched for age, sex pubertal stage. Behavioral reactivity assessed three observational situations (parents at home, two caregivers...

10.1371/journal.pone.0005289 article EN cc-by PLoS ONE 2009-08-25
Ludovic Lhermitte Sylvain Barreau Daniela Morf Paula Fernández Georgiana Grigore and 95 more Susana Bárrena Maaike de Bie Juan Flores‐Montero Monika Brüggemann Ester Mejstříková Stefan Nierkens Leire Burgos Joana Caetano Giuseppe Gaipa Chiara Buracchi Elaine Sobral da Costa Łukasz Sędek Tomasz Szczepański Carmen-Mariana Aanei Alita van der Sluijs-Gelling Alejandro Hernández-Delgado Rafael Fluxá Quentin Lécrevisse Carlos E. Pedreira Jacques J. M. van Dongen Alberto Órfão Vincent H. J. van der Velden Jacques J. M. van Dongen W. Marieke Bitter Brad Lubbers C.I. Teodosio Mihaela Zlei Alita J. van der Sluijs‐Gelling F. de Bie Sandra de Bruin-Versteeg Mirjam van der Burg Marco W. Schilham Vincent H. J. van der Velden Anton W. Langerak Jeroen te Marvelde A.E. Bras Joyce Schilperoord‐Vermeulen Romana Jugooa Kim C. Heezen Alberto Órfão Júlia Almeida María‐Belén Vidriales Juan Flores‐Montero Martín Pérez‐Andres Sergio Matarraz L. Martín Quentin Lécrevisse J.J. Pérez-Morán N. Puig António Almeida María Gomes da Silva Tiago Faria Monika Brüggemann Matthias Ritgen Monika Szczepanowski Saskia Kohlscheen Anna Laqua E. Harbst Jürgen Finke Vahid Asnafi Ludovic Lhermitte Eugénie Duroyon Jan Trka Ondřej Hrušák Tomáš Kalina Ester Mejstříková Michaela Nováková Daniel Thürner Veronika Kanderová Tomasz Szczepański Łukasz Sędek Joanna Bulsa Łukasz Słota Jan Kulis Carlos E. Pedreira Elaine Sobral da Costa Stefan Nierkens Anneke de Jong Arjan de Koning Margarida Lima Andres Santos Sebastian Böttcher Sandra Lange R. Engelmann Daniel Paape C. Machka Giuseppe Gaipa C. Burracchi Cristina Bugarin Eduardo López‐Granados Lucía del Pino Molina Lydia Campos-Guyotat Carmen Aanei Jesús F. San Miguel Bruno Paiva

Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide toward the relevant panel and final diagnosis. In this study, we validated algorithm automated (database-supported) gating identification (AGI tool) cell subsets within samples stained with ALOT. A reference database normal peripheral blood (PB, n = 41) bone marrow (BM; 45) analyzed ALOT was constructed, served as a AGI tool automatically...

10.1038/s41379-020-00677-7 article EN cc-by Modern Pathology 2020-09-30

Purpose: To model CML progression in vitro and generate a blast crisis (BC-CML) order to identify new targets. Methods: Three different CML-derived iPSC lines were mutagenized with the alkylating agent ENU on daily basis for 60 days. Cells analyzed at D12 of hematopoietic differentiation their phenotype, clonogenicity, transcriptomic profile. Single-cell RNA-Seq analysis has been performed three time points during ENU-treated untreated cells. Results: One CML-iPSCs, compared its...

10.3390/cells12040598 article EN cc-by Cells 2023-02-12

Abstract Background Multiparametric flow cytometry (MFC) was recently reported to be a helpful additional tool in the diagnosis of myelodysplastic syndromes (MDS). However, numerous aberrancies have been that makes their evaluation difficult as part routine diagnosis. Methods Here, we validated 1‐tube panel for granulocytic and monocytic maturation by MFC correlated our findings with prognosis MDS. A total 251 samples MDS suspicion were prospectively analyzed compared an internal reference...

10.1002/cyto.b.21843 article EN Cytometry Part B Clinical Cytometry 2019-09-09

We report two cases of treatment failure in patients with osteoarticular infection associated Staphylococcus aureus bacteremia and receiving daptomycin. Using a published population-pharmacokinetic model daptomycin blood level these patients, area under the curve (AUC) was calculated compared to pharmacological target. For first patient, treated 6 mg/kg every 48 hours due acute renal then 24 hours, AUC 820 mg×h×L-1, minimal concentration 23.5 mg/L confirming right dose adjustment absence...

10.5414/cp202538 article EN International Journal of Clinical Pharmacology and Therapeutics 2016-08-11

Although anti-CD38 monoclonal antibodies have improved the prognosis of relapsed/refractory multiple myeloma (RRMM), some patients still experience early relapses with poor outcomes. This present study evaluated predictive value FDG PET/CT parameters for RRMM prior to initiating treatment. We included 38 consecutive who underwent a scan treated at our institution relapse. The median PFS was 12.5 months and OS not reached. 42% had an initial ISS score 1, 37% 2, 21% 3. presence >3 focal...

10.3390/cancers13174323 article EN Cancers 2021-08-27

An anonymous donation of bone elements to the Laboratory Anthropology, Archeology, Biology (LAAB) (UVSQ/Paris-Saclay) once again raises question future heritage and university osteological collections. It allows alert about fragility collections risk their disappearance. The treatment, conservation human remains are currently at heart intense debates among archeology professionals as well within legislative apparatus in France. French law concerning valorization ancient vague, which...

10.1016/j.jemep.2024.100974 article EN cc-by-nc Ethics Medicine and Public Health 2024-01-01

A 79-year-old man presented to the hospital with painful and necrotic leg ulcers, petechiae of ankles a livedoid rash lower limbs. full blood count showed haemoglobin concentration 128 g/l, leucocytes 8.39 × 109/l platelets 93 109/l. Examination film revealed platelet clumps some pale lilac amorphous deposits between red cells; there were also many neutrophils compressed or distorted nuclei due phagocytosis these precipitates (images, May-Grünwald-Giemsa stain, ×100 objective). These...

10.1111/bjh.16634 article EN British Journal of Haematology 2020-04-01

Introduction: Although immunotherapy with monoclonal antiCD38 antibody has improved prognosis of relapse/refractory multiple myeloma (RRMM), some patients experience early relapse a dismal outcome. 18F-FDG PET/CT is now recommended for the visualization disease activity in both newly diagnosed and RRMM patients. It also been used prediction survival outcome treated allogeneic stem cell transplant. This study evaluated predictive impact PET parameters before initiating therapy. Methods:...

10.1002/hon.99_2881 article EN Hematological Oncology 2021-06-01
Coming Soon ...